-
Goldman Sachs Starts Generate Biomedicines (GENB) at Buy
-
Guggenheim Starts Generate Biomedicines (GENB) at Buy
-
Generate Biomedicines plans up to $425 million U.S. IPO
-
Generate Biomedicines (GENB) files for 25M share IPO at $15-$17/sh
-
Generate Biomedicines (GENB) files for proposed IPO

